Project Grant R01HD113720

Award Date 9/4/24
Completion Date 8/31/29
Dollars Obligated $10K
Funding Federal Agency
Office of the Director
Federal Grant Program
93.310
Assistance Type
Project Grant
Place of Performance
Colorado, USA
Similar Awards
This Project Grant award of $429,000 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to understand the cellular and synaptic mechanisms underlying cognitive disabilities in Down syndrome. The award to the University of Colorado-Denver will utilize a novel combination of two-photon microscopy, electrophysiology, chemogenetics, and pharmacological...
The federal Cooperative Agreement award U01HD116463, titled "The Infant Down Syndrome Brain and Behavior Study", is funded by the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310). The $2,927,457 award will support a longitudinal study to collect multimodal neuroimaging, cognitive/behavioral data, and social communication measures in a cohort of 100 infants with Down syndrome and 50 typically developing controls. The study aims to...
This Project Grant award of $3,317,325.00 from the National Institutes of Health's Trans-NIH Research Support program (CFDA 93.310) will support research to investigate the role of immune dysregulation and nerve growth factor (NGF) dysfunction in the development of Alzheimer's disease (AD) in individuals with Down syndrome (DS). The key objectives are to: 1) elucidate the relationships between immune deregulation, NGF dysmetabolism, and AD hallmarks in DS brain tissue and cell cultures; 2)...
This federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $2,357,335 to study neuronal dysfunction in Down syndrome (DS) and its link to Alzheimer's disease (AD). The key products and services delivered under this award include: Utilizing induced pluripotent stem cell (iPSC)-derived cortical organoids and assembloids to examine the cellular, transcriptomic, and motility-related...
This Project Grant award from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), provides $661,575 to Children's Hospital LOS Angeles to conduct a 5-year study on Down Syndrome Regression Disorder (DSRD). The research aims to utilize neurodiagnostic studies, proteomic, and metabolomic analyses to compare individuals with DSRD to those with Down Syndrome who do not...
This $2,598,199 Cooperative Agreement, awarded by the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), will support a multi-center, multi-disciplinary research project titled "Advancing the Lives & Health of Youth and Young Adults with Down Syndrome (ALLY-DS)." The project aims to establish a diverse cohort of individuals with Down syndrome for comprehensive longitudinal phenotyping, including multi-omics data...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) in the amount of $195,041 supports research to elucidate the role of cardiovascular disease in the development of Alzheimer's disease in individuals with Down syndrome. The 2-year project will leverage data from the Alzheimer's Biomarker Consortium for Down Syndrome to develop innovative statistical models combining Bayesian inference and machine learning. These methods will explore...
The National Institutes of Health (NIH) awarded a $2,507,286 Project Grant under the Trans-NIH Research Support program (CFDA 93.310) to investigate therapies for Down Syndrome Regression Disorder (DSRD). The 3-year grant, which commenced on September 1, 2024, supports a comparative clinical trial evaluating the safety and efficacy of three potential DSRD treatments: the benzodiazepine lorazepam, intravenous immunoglobulin (IVIG), and the JAK inhibitor tofacitinib. The project aims to advance...
The National Institutes of Health (NIH) Office of the Director awarded a Project Grant of $1,896,457.00 under the Trans-NIH Research Support program (CFDA 93.310) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), for the project "BRAIN DEVELOPMENT IN DOWN SYNDROME DURING FETAL AND EARLY POSTNATAL AGES". The grant, awarded on Sep 18, 2024, aims to confirm earlier findings on brain abnormalities in Down syndrome (DS) using advanced...
The Department of Health and Human Services, through the Trans-NIH Research Support program (CFDA 93.310), has awarded a $1,999,508 Cooperative Agreement to RTI International and Emory University to establish the INCLUDE Down Syndrome Clinical Cohort Coordinating Center (DS-4C). The DS-4C will serve as the central hub to coordinate and integrate all components of the INCLUDE Down Syndrome Cohort Development Program, including overseeing protocol development, facilitating data collection and...

RISK FOR SEVERE/PROFOUND INTELLECTUAL DISABILITY IN DOWN SYNDROME - ABSTRACT DOWN SYNDROME (DS) PREDISPOSES INDIVIDUALS TO A WIDE RANGE OF COGNITIVE OUTCOMES, WITH SOME INDIVIDUALS ACQUIRING MORE ADVANCED COGNITIVE SKILLS AND OTHERS DEMONSTRATING SEVERE OR PROFOUND LEVELS OF INTELLECTUAL DISABILITY (S/PID). THE EARLY ORIGINS OF S/PID IN INDIVIDUALS WITH DS ARE POORLY UNDERSTOOD, AND INDIVIDUALS WITH DS AND S/PID ARE OFTEN UNDERREPRESENTED IN THE SCIENTIFIC LITERATURE. THIS PROJECT WILL ADDRESS AN IMPORTANT GAP IN OUR KNOWLEDGE AND ESTABLISH A NOVEL ACCOUNT OF VARIABILITY IN COGNITIVE SKILL ACQUISITION IN DS WITH AN EMPHASIS ON UNDERSTANDING THOSE CHILDREN WHO DEMONSTRATE THE MOST PRONOUNCED LEVELS OF EARLY COGNITIVE DELAY. WE WILL CHARACTERIZE EARLY COGNITIVE GROWTH IN YOUNG CHILDREN WITH DS AND EXAMINE THE ASSOCIATION BETWEEN SEVERE/PROFOUND EARLY COGNITIVE DELAYS AND BEHAVIOR, BIOMEDICAL FACTORS, AND MOLECULAR BIOSIGNATURES KNOWN TO BE AFFECTED BY DS, SUCH AS VARIOUS INFLAMMATORY PROCESSES, ELEVATED NEURODEGENERATION AND NEUROINFLAMMATION BIOMARKERS, DYSREGULATION OF THE GROWTH HORMONE (GH)-IGF1 AXIS, AND DYSREGULATED METABOLISM. TO ACHIEVE THIS GOAL, WE WILL RECRUIT 90 CHILDREN WITH DS TO BE ASSESSED AT THREE DATA WAVES (WAVE 1 = 12 MONTHS; WAVE 2 = 24 MONTHS; WAVE 3 = 36 MONTHS) AND WE WILL CONDUCT COMPREHENSIVE COGNITIVE AND BROADER DEVELOPMENTAL EVALUATIONS. BLOOD SAMPLES WILL BE COLLECTED CONCURRENTLY WITH EACH VISIT AND BIOMEDICAL HISTORY INFORMATION WILL BE OBTAINED. WE WILL THEN MODEL LATENT GROWTH TRAJECTORIES ALONG EARLY COGNITIVE AND OTHER DEVELOPMENTAL DOMAINS AND EXAMINE THE ASSOCIATION BETWEEN GROWTH PROFILES, BIOMEDICAL HISTORY, MOLECULAR BIOSIGNATURES, AND SEVERE/PROFOUND DEGREES OF EARLY COGNITIVE DELAY AT WAVE 3. THIS INTEGRATED APPROACH TO CHARACTERIZING HETEROGENEITY IN COGNITIVE DELAYS IN DS CAN POTENTIALLY TRANSFORM THE NATURE OF TREATMENTS AND INTERVENTIONS FOR THOSE INDIVIDUALS WHO ARE IN NEED OF THE MOST INTENSIVE DEGREE OF LIFELONG COMMUNITY SUPPORT.

Posted 9/3/24